• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec8
Syndax Pharmaceuticals Announces Positive Trial Results for Revuforj® in AML at ASH Annual Meeting
11:50
Nov24
Barclays Maintains Overweight Rating and Raises Target Price for Syndax Pharmaceuticals
18:57
Nov14
H.C. Wainwright and J.P. Morgan Reiterate Buy Rating on Syndax Pharmaceuticals
11:42
Nov4
Syndax Pharmaceuticals Reports Exceeding EPS Expectations for Q3, Stock Price Rises
17:23
Lawson Reiterates Buy Rating on Syndax Pharmaceuticals
07:56
Syndax Pharma released FY2025 9 Months Earnings on November 3 After-Market EST, with actual revenue of USD 58 M and EPS of USD -1.8167
00:00

Schedules & Filings

Schedules
Filings
Nov3
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 45.87 M, Net Income -60.72 M, EPS -0.7009

Aug4
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 37.96 M, Net Income -71.85 M, EPS -0.8321

May5
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 20.04 M, Net Income -84.85 M, EPS -0.9846

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
RPGL
0.6834
+159.55%
+0.420
BNAI
2.505
+108.75%
+1.305
SOPA
2.930
+60.99%
+1.110
ILAG
0.5237
+48.91%
+0.172
MASK
0.2606
+42.40%
+0.078
GVH
3.560
+36.92%
+0.960
CCTG
0.1750
+34.31%
+0.045
SIDU
2.570
+33.16%
+0.640
THH
22.390
+32.21%
+5.455
TDIC
0.2566
+28.94%
+0.058
View More